Introduction
============

Prostate cancer is a major public health problem, as it is the most common cancer diagnosed in men and the leading cause of cancer deaths in the United States. Although recent discoveries in cancer genetics have improved our understanding of prostate carcinogenesis, much remains to be explained concerning the molecular and genetic events important in prostate cancer progression.

Epigenetics is defined as the study of heritable changes in gene expression that are not explained by changes in DNA sequence. Three important mechanisms lead to epigenetic events: DNA methylation, histone modification, and RNA-associated silencing. Among these mechanisms, DNA methylation and histone modification are related to chromatin remodeling have been extensively studied, both often interacting for the control of gene expression ([@b72-grsb-2007-313]; [@b146-grsb-2007-313]; [@b182-grsb-2007-313]). Unlike genetic alterations, which are permanent alterations of DNA sequence, epigenetic changes in tumor and normal cells may have "phenotypic plasticity". This allows cells to alter their gene expression pattern and adapt to their environment.

In recent years, with the availability of new technologies to further understand the molecular mechanisms in cancer, it has become clear that epigenetic events play a crucial role in cancer ([@b39-grsb-2007-313]). In prostate cancer, it has been shown that DNA methylation and histone modification are important epigenetic mechanisms for changes in gene regulation that can lead to tumorigenesis. These two mechanisms, closely related, sometimes interact to control gene expression ([@b171-grsb-2007-313]; [@b96-grsb-2007-313]).

In this review, we discuss some of the genes that have been described to frequently be dysregulated in prostate cancer as a consequence of aberrant epigenetic alterations such as DNA methylation and histone modifications.

Prostate Cancer: Carcinogenesis
===============================

In general, prostate cancer has been described as heterogeneous and multifocal, with different clinical and morphological characteristics ([@b142-grsb-2007-313]). Although prostate cancer is generally an indolent disease, 25%--30% of tumors are clinically aggressive ([@b48-grsb-2007-313]; [@b20-grsb-2007-313]).

Prostate cancer is thought to occur initially as an androgen-dependent tumor that, in some cases, can progress to a highly invasive androgen-independent tumor. When the disease is advanced, the tumor spreads locally, metastasizes to the pelvic lymph nodes, and to distant areas like the bone. Once metastasis is initiated, prostate cancer is incurable ([@b181-grsb-2007-313]; [@b137-grsb-2007-313]; [@b3-grsb-2007-313]). During prostate carcinogenesis, multiple cellular and molecular events including genetic changes occur ([@b28-grsb-2007-313]).

In adults, two main types of prostate disease occur: benign prostatic hyperplasia (BPH) and prostate cancer, which is believed to derive from prostatic intraepithelial neoplasia (PIN) lesions ([@b164-grsb-2007-313]; [@b19-grsb-2007-313]). Based on their relationship to prostatic disease, three distinct morphological zones have been described in the prostate: (i) the peripheral zone, primarily the site where prostate carcinoma arise; (ii) the transition zone, where BPH mainly occurs; and (iii) the central zone which is relatively resistant to carcinoma and other disease ([@b106-grsb-2007-313]; [@b107-grsb-2007-313]). In prostate cancer development, transformation occurs from benign epithelial glands to pre-malignant lesions and to invasive carcinoma. Some morphological lesions have been proposed as potential precursor of prostate cancer, such as high-grade PIN ([@b19-grsb-2007-313]) and proliferative inflammatory atrophy (PIA) ([@b27-grsb-2007-313]; [@b29-grsb-2007-313]).

Background on Epigenetic Events
===============================

Epigenetic mechanisms such as DNA methylation and histone modification play an essential role in many molecular and cellular alterations associated with the development and progression of prostate cancer ([@b135-grsb-2007-313]; [@b95-grsb-2007-313]; [@b149-grsb-2007-313]). Although, the majority of the epigenetic changes, as discussed below, occur in prostate cancer, some changes have been characterized in BPH and recent data showed a unique set of genes associated with BPH progression ([@b96-grsb-2007-313]; [@b133-grsb-2007-313]). The role of methylation in regulating alterations of gene expression in BPH has not been established, however.

DNA methylation refers to the covalent bounding of a methyl group specifically to the dinucleotide CpG. This is catalyzed by the family of enzymes, the DNA methyltransferases. It is thought that DNA methylation alters chromosome structure and defines regions for transcriptional regulation. Clusters of CpG sites are found dispersed around the genome and are referred to as CpG islands, stretches of DNA ranging from 0.5 to 5 kb with a GC content of at least 50% ([@b21-grsb-2007-313]). These islands are found in the promoter region of about 60% of genes, in exons and introns, and in repetitive elements. Most CpG islands in the promoter regions are unmethylated whereas CpG islands in intronic regions and repetitive sequences are heavily methylated, perhaps to help the cell identify regions for gene transcription.

Two types of DNA methylation alterations have been demonstrated in human cancers. The first refers to global hypomethylation where the genomes of cancer cells show decreased methylation compared to normal cells ([@b31-grsb-2007-313]). This hypomethylation is primarily due to the loss of methylation in repetitive elements and other non-transcribed regions of the genome, which results in genomic instability. The second type of methylation alteration in cancer cells is the methylation of CpG islands that lie in promoter regions of tumor suppressor and other regulatory genes that are normally unmethylated. The promoter regions of these genes are inactivated by methylation and their gene expression silenced. This is referred to as gene hypermethylation.

Alterations in DNA methylation often work in concert with changes in chromatin structure modulated through histone modification to silence gene expression. DNA methylation allows for the binding of DNA methylation-specific binding proteins such as MECP2, MBD1, MBD2, which acts to recruit inhibitors and induce histone modification to its inactive state ([@b171-grsb-2007-313]; [@b96-grsb-2007-313]). In addition, methylation in or near promoter sites may work to directly inhibit the binding of transcription factors to their recognition sequences ([@b4-grsb-2007-313]).

Hypermethylation and Prostate Cancer
====================================

DNA hypermethylation has been the most common and best-characterized epigenetic event in cancer, including prostate cancer. In prostate cancer, a large number of genes have been found hypermethylated. These genes are correlated with pathological grade or clinical stage, and thought to contribute to initiation and progression of the disease. These genes, shown in [Table 1](#t1-grsb-2007-313){ref-type="table"} and discussed below, are involved in a variety of cellular pathways such as DNA damage repair (Glutathione S Transferase P1; O^6^-Methylguanine-DNA-Methyltransferase), signal transduction (RASSF1A), adhesion (Endothelin Receptors, E-cadherin, CD44, Adenomatous Polyposis Coli gene, and galectins), hormonal responses (Retinoic Acid Receptor; Androgen Receptor, and Estrogen Receptor), apoptosis (Death-Associated Protein Kinase), cell growth, invasion and metastasis (Tissue Inhibitors of Metalloproteinases, and galectins), and cell cycle control (cyclins, cyclin dependent kinases, and their inhibitors). A schematic depicting the different stages in prostate cancer and related hypermethylated genes is shown in [Figure 1](#f1-grsb-2007-313){ref-type="fig"}.

Glutathione S transferases
--------------------------

The glutathione S transferases (GSTs) are a family of enzymes involved in intracellular detoxification of xenobiotics and carcinogens by conjugation to glutathione, ultimately protecting cells from DNA damage and cancer initiation ([@b144-grsb-2007-313]; [@b6-grsb-2007-313]). Several isoforms of human GST have been described: five cytosolic forms---alpha, mu, pi, sigma, and theta---and one membrane form. Among these genes, pi isoform (GSTP) is the most ubiquitously expressed and well-studied gene ([@b52-grsb-2007-313]; [@b55-grsb-2007-313]).

In prostate cancer, decrease or loss of GSTP1 expression as a result of gene promoter methylation is the most frequent epigenetic alteration observed ([@b91-grsb-2007-313]; [@b105-grsb-2007-313]; [@b178-grsb-2007-313]; [@b77-grsb-2007-313]; [@b176-grsb-2007-313]; [@b180-grsb-2007-313]). Silencing of GSTP1 has been shown in 70% to 100% of cancerous lesions, 50%--70% of PIN lesions, whereas it has been rarely detected in normal prostate or BPH tissues ([@b11-grsb-2007-313]; [@b67-grsb-2007-313]; [@b68-grsb-2007-313]; [@b178-grsb-2007-313]; [@b111-grsb-2007-313]; [@b41-grsb-2007-313]). Recently, GSTP1 gene methylation has been found in a subset of PIA lesions, which are believed to be a precursor for tumors ([@b111-grsb-2007-313]). Also, racial differences have been correlated to GSTP1 methylation status ([@b175-grsb-2007-313]; [@b177-grsb-2007-313]).

O^6^-Methylguanine-DNA-Methyltransferase
----------------------------------------

The DNA-alkyl repair gene O^6^-Methylguanine-DNA-Methyltransferase (MGMT) is involved in DNA damage repair; it removes mutagenic and cytotoxic alkyl adducts from O^6^-guanine in DNA ([@b131-grsb-2007-313]; [@b33-grsb-2007-313]). Hypermethylation of the MGMT promoter leads to the loss of its function in various carcinomas ([@b153-grsb-2007-313]); however, prostate cancer data are not clear. Indeed, some studies have reported a lack of significant MGMT methylation in prostate tumors ([@b105-grsb-2007-313]; [@b178-grsb-2007-313]; [@b180-grsb-2007-313]), whereas others have detected moderate to high levels ([@b77-grsb-2007-313]; [@b83-grsb-2007-313]).

RASSF1A
-------

RAS proteins have a major function in extra-cellular signals transduction regulating cell growth, survival and differentiation. Many RAS effectors are known as onco-proteins involved in different mechanisms,---apoptosis, contact inhibition, tumor phenotype-, when over-expressed; on the other hand, less is known regarding the effectors acting as tumor suppressor ([@b169-grsb-2007-313]; [@b154-grsb-2007-313]; [@b23-grsb-2007-313]). Among a new family of genes encoding RAS-binding proteins, RAS association domain family 1 gene (RASSF1) has been identified as a tumor suppressor in many carcinomas ([@b25-grsb-2007-313]). RASSF1 gene mainly consists of RASSF1A and RASSF1C transcripts that are expressed on two distinct CpG promoters and present in normal human tissues; however, in many cancer, RASSF1A is inactivated and has been correlated to methylation ([@b24-grsb-2007-313]).

In prostate cancer, RASSF1A methylation is either frequently detected in tissue samples or not ([@b77-grsb-2007-313]; [@b180-grsb-2007-313]; [@b176-grsb-2007-313]; [@b177-grsb-2007-313]; [@b105-grsb-2007-313]; [@b98-grsb-2007-313]; [@b86-grsb-2007-313]) and in the latter case it has been a correlated with prostate-specific antigen level or disease stage ([@b77-grsb-2007-313]; [@b180-grsb-2007-313]; [@b176-grsb-2007-313]). Furthermore, several findings indicate that RASSF1A methylation occurs at different stages of prostate cancer development as reported in PIN lesions ([@b77-grsb-2007-313]; [@b2-grsb-2007-313]) and advanced tumors ([@b77-grsb-2007-313]; [@b105-grsb-2007-313]; [@b98-grsb-2007-313]).

Endothelin receptors
--------------------

The endothelin (ET), a family of peptides, consists of three isotypes that have potent vasoconstructive properties; they are expressed differently in various cells and tissues ([@b62-grsb-2007-313]; [@b140-grsb-2007-313]). ET-1 isotype is predominant and produced in endothelial cells. It is a growth regulatory peptide involved in cell proliferation ([@b179-grsb-2007-313]; [@b125-grsb-2007-313]). Two receptors ETA and ETB have been identified; they differ from each other, but belong to the same family of heptahelical G-protein-coupled receptors. Both are found in various cells and tissues with different levels of expression ([@b145-grsb-2007-313]; [@b45-grsb-2007-313]). The receptor A binds highly with equivalent affinity to ET-1 and ET-2 but not to ET-3, whereas receptor B is nonselective and binds with equal affinity to the three isotypes ([@b145-grsb-2007-313]; [@b45-grsb-2007-313]).

In prostate cancer, ET-1 is produced by primary and metatstatic cells in vivo ([@b117-grsb-2007-313]). As prostate cancer progresses, increased expression of ET receptor A is observed, whereas the expression of receptor B is reduced or lost ([@b42-grsb-2007-313]; [@b118-grsb-2007-313]). Furthermore, the endothelin receptor B gene has been frequently found methylated in prostate cancer samples, and to a lesser frequency in benign samples ([@b119-grsb-2007-313]; [@b130-grsb-2007-313]; [@b69-grsb-2007-313]; [@b176-grsb-2007-313]; [@b180-grsb-2007-313]).

E-cadherin
----------

E-cadherin is a transmembrane glycoprotein, and a member of the cadherin family of cell adhesion molecules that mediates cell-cell adhesion via calcium-dependent interactions ([@b78-grsb-2007-313]; [@b60-grsb-2007-313]). E-cadherin, which may function as a tumor suppressor gene in invasion and metastasis, has been shown to be decreased or absent in many cancers, and is predictive of poor patient outcome ([@b124-grsb-2007-313]; [@b162-grsb-2007-313]; [@b136-grsb-2007-313]). In prostate cancer, decreased expression of E-cadherin, which is related to tumor progression, has been correlated to hypermethylation of the promoter in patients' samples and human cell lines as well ([@b75-grsb-2007-313]; [@b105-grsb-2007-313]; [@b177-grsb-2007-313]; [@b180-grsb-2007-313]; [@b46-grsb-2007-313]; [@b94-grsb-2007-313]).

CD44
----

CD44 is a polymorphic cell adhesion molecule that belongs to a family of integral membrane glycoprotein; CD44 plays a role in cell adhesion and cell-matrix interactions as a receptor for hyaluronic acid and osteopontin ([@b115-grsb-2007-313]; [@b141-grsb-2007-313]; [@b163-grsb-2007-313]; [@b172-grsb-2007-313]). In prostate cancer, it has been suggested that CD44 may act as a metastasis suppressor gene, and its down-regulation is associated with tumor progression and metastasis ([@b110-grsb-2007-313]; [@b157-grsb-2007-313]; [@b103-grsb-2007-313]). The exact mechanism of CD44 down-regulation remains elusive; however an epigenetic mechanism, methylation, is clearly involved in this effect. Indeed, a number of studies, both in human samples and cell lines, have shown hypermethylation at the CpG islands in the promoter region of CD44, resulting in the decrease of its expression ([@b74-grsb-2007-313]; [@b167-grsb-2007-313]; [@b82-grsb-2007-313]; [@b176-grsb-2007-313]; [@b177-grsb-2007-313]).

Adenomatous polyposis coli
--------------------------

The adenomatous polyposis coli (APC) gene encodes a multifunctional protein that plays a role in Wnt signaling pathway, cell migration, cell adhesion, and mitosis; it is also known to act as a tumor suppressor gene in familial adenomatous polyposis ([@b38-grsb-2007-313]; [@b116-grsb-2007-313]).

In prostate cancer development, APC hypermethylation has been detected in its earliest stage, in more than 30% of PIN samples, and as the disease progresses the frequency becomes higher ([@b77-grsb-2007-313]; [@b105-grsb-2007-313]; [@b180-grsb-2007-313]).

Galectins
---------

Galectins are a family of animal lectins that act by specifically binding β-galactosides. Presently, fifteen members have been identified; most of them are ubiquitously expressed in various tissues, whereas others are more specific ([@b92-grsb-2007-313]; [@b97-grsb-2007-313]). Among the different members, two galectins, 1 and 3 are the most studied. In cancer, galectins play a role in a number of biological functions such as adhesion, proliferation, differentiation, invasion and metastasis. They exert their functions both extra- and intra-cellularly; however, the mechanism by which they regulate these different functions is still unknown ([@b166-grsb-2007-313]; [@b97-grsb-2007-313]).

In prostate cancer progression, galectin-3 is mainly studied; and different reports show a down-regulation of this gene ([@b32-grsb-2007-313]; [@b127-grsb-2007-313]). Galectin-3 is shown to have dual activity, acting as an anti-tumor protein or aid in tumor progression, dependent on its localization in the nucleus or cytoplasm, respectively ([@b165-grsb-2007-313]; [@b13-grsb-2007-313]). Furthermore, very recently, it has been shown for the first time in prostate cancer cell lines that silencing of galectin-3 expression is regulated by promoter hypermethylation ([@b1-grsb-2007-313]).

Retinoic acid receptorβ
-----------------------

The retinoic acid receptor (RAR) family, which comprises three subtypes (α, β, and γ), belongs to the superfamily of steroid/thyroid hormone receptors ([@b34-grsb-2007-313]; [@b26-grsb-2007-313]). Each subtype consists of several isoforms resulting from different promoter usage and alternative splicing. Among these receptors, RARβ2, expressed in most tissues, has been extensively studied in various cancers where it acts as a tumor suppressor gene ([@b40-grsb-2007-313]; [@b51-grsb-2007-313]; [@b99-grsb-2007-313]; [@b63-grsb-2007-313]). Loss or down-regulation of RARβ2 expression appears to be both at genetic and epigenetic levels; in the latter it is associated with methylation in the promoter region ([@b152-grsb-2007-313]; [@b63-grsb-2007-313]; [@b170-grsb-2007-313]).

In prostate cancer, methylation of RARβ2 in the promoter region is frequently detected in primary tumors and very high in hormone-refractory tumors, but not in BPH and normal samples as well ([@b113-grsb-2007-313]; [@b105-grsb-2007-313]; [@b178-grsb-2007-313]: [@b176-grsb-2007-313]). Furthermore, methylation also occurs at a low level in PIN samples ([@b70-grsb-2007-313]). Taken together, it seems that RARβ2 methylation is an early event in prostate cancer, and an indicator of aggressiveness as the disease progresses to late stages ([@b113-grsb-2007-313]; [@b178-grsb-2007-313]).

Androgen receptor
-----------------

Androgens such as testosterone and 5α-dihydrotestosterone are the main steroid hormones in the prostate. These hormones act through the androgen receptor (AR), which belongs to the family of steroid/thyroid nuclear receptors ([@b53-grsb-2007-313]). The AR gene expression in prostate cancer progression occurs through different mechanisms including amplification, mutations, and ligand-independent activation ([@b168-grsb-2007-313]; [@b158-grsb-2007-313]; [@b160-grsb-2007-313]). Furthermore, androgen independence is a feature of terminal stages in metastatic prostate cancer and the loss of AR expression in those cells appears to be at the transcriptional level ([@b159-grsb-2007-313]; [@b174-grsb-2007-313]) rather than involving deletion or mutation mechanisms ([@b22-grsb-2007-313]).

The presence of CpG islands in the AR suggests that this gene might be regulated by methylation. In prostate cancer, a number of studies have indeed shown methylation in the promoter region of the AR leading to its inactivation; however, the frequency of methylation seems to be low ([@b65-grsb-2007-313]; [@b81-grsb-2007-313]; [@b112-grsb-2007-313]; [@b147-grsb-2007-313]; [@b178-grsb-2007-313]). In addition, methylation appears to be more prevalent in hormone refractory tumors than in primary tumors ([@b81-grsb-2007-313]; [@b112-grsb-2007-313]).

Estrogen receptors
------------------

Estrogens are steroid hormones, which are believed to play an important role in prostate carcinogenesis ([@b14-grsb-2007-313]; [@b15-grsb-2007-313]). They act through intracellular receptors, which are also effectors involved in proliferation, differentiation, and development of prostate cells ([@b14-grsb-2007-313]; [@b15-grsb-2007-313]). The estrogen receptors (ERs) are members of a nuclear receptor superfamily of ligand-activated transcription factors; at present, two receptors, ER-α and ER-β, have been identified, shown to be expressed in a cell and tissue specific manner, and involved in the regulation of the normal function of reproductive tissues ([@b109-grsb-2007-313]; [@b47-grsb-2007-313]). Several studies have reported the presence of both receptors in normal and cancerous prostate tissues, as well as the loss or down-regulation of ER-β during prostate cancer development ([@b138-grsb-2007-313]; [@b61-grsb-2007-313]; [@b90-grsb-2007-313]; [@b5-grsb-2007-313]).

The epigenetic mechanism, namely methylation in promoter regions of ER-α and ER-β has been associated with decreased or loss of expression of these two genes in prostate cancer. Both receptors are frequently inactivated by CpG methylation in tumor samples and cell lines as well ([@b93-grsb-2007-313]; [@b89-grsb-2007-313]; [@b122-grsb-2007-313]; [@b147-grsb-2007-313]; [@b180-grsb-2007-313]). However, regarding ER-β, a high frequency of methylation in the promoter region of the gene has been observed at the early stages of the disease, whereas this frequency declined in metastatic tumors ([@b122-grsb-2007-313]; [@b183-grsb-2007-313]). It has also been reported the methylation of ER-α and ER-β in BPH but to a lesser extent than in prostate cancer tumors ([@b93-grsb-2007-313]; [@b122-grsb-2007-313]).

Death-associated protein kinase
-------------------------------

The death-associated protein kinase (DAPK) family is a member of the pro-apoptotic calcium-regulated serine/threonine kinases; it is ubiquitously expressed in tissues, and its inactivation leads to the loss of important apoptotic pathway ([@b7-grsb-2007-313]). Although different mechanisms may affect DAPK inactivation, it has been shown that mainly aberrant methylation is responsible for silencing of this gene. Thus, DAPK has been found methylated in BPH and prostate cancer samples, but not in PIN samples ([@b105-grsb-2007-313]; [@b178-grsb-2007-313]; [@b77-grsb-2007-313]; [@b180-grsb-2007-313]).

Tissue inhibitors of metalloproteinases
---------------------------------------

The tissue inhibitors of metalloproteinases (TIMPs) belong to a family of homologous proteins inhibitors that control the activity of matrix metalloproteinases (MMPs) ([@b44-grsb-2007-313]). Presently, four members have been identified; they are involved in a number of biological functions such as cell growth, apoptosis, invasion, metastasis and angiogenesis ([@b37-grsb-2007-313]; [@b87-grsb-2007-313]).

Few reports investigated the possible epigenetic mechanisms underlying the down-regulation of TIMPs in prostate cancer. Methylation patterns have been studied for TIMP-3 and very recently for TIMP-2. TIMP-3 methylation is detected at low levels both in prostate carcinoma and BPH ([@b178-grsb-2007-313]; [@b180-grsb-2007-313]; [@b71-grsb-2007-313]). Moreover, Jeronimo et al. reported that this event might be age-dependent and zone-dependent ([@b71-grsb-2007-313]). Furthermore, a very recent study of prostate cell lines and primary tumors shows that TIMP-2 down-regulation is associated with methylation of the promoter region ([@b134-grsb-2007-313]).

Cell cycle genes
----------------

A hallmark of tumor cells is their inability of growth control, which is often associated with lack of regulation of the cell cycle. The cell cycle has multiple checkpoints that are controlled by many molecular regulators; often the regulatory molecules affected in cancer are those involved in the control of the G1/S transition of the cell cycle ([@b132-grsb-2007-313]; [@b8-grsb-2007-313]; [@b76-grsb-2007-313]). The regulatory proteins involved in the cell cycle include the retinoblastoma protein (RB), cyclins, cyclin dependent kinases (CDKs), and CDK inhibitors (CDKIs), all of which have been implicated in tumor progression ([@b151-grsb-2007-313]). CDKIs have been described as negative regulators of the cell cycle, and subsequently considered as tumor suppressor genes. They consist of two families, the INK4 family and the CIP/KIP (kinase inhibitor protein) family. The INK4 family is composed of four members CDKN2A or p16, CDKN2B or p15, CDKN2C or p18, and CDKN2D or p19, which specifically inhibits CDKs 4 and 6 ([@b139-grsb-2007-313]; [@b126-grsb-2007-313]). The CIP/KIP family includes CDKN1A or p21, CDKN1B or p27, and CDKN1C or p57; they inhibit most CDKs ([@b150-grsb-2007-313]). Genetic and/or epigenetic alterations in regulatory molecules and growth pathways directly or indirectly involved in cell cycle control may result in gene inactivation and consequently to deregulation of cell cycle progression, therefore contributing to the pathogenesis of cancer ([@b104-grsb-2007-313]).

In prostate cancer, cell cycle genes can be inactivated by a number of mechanisms such as deletion, point mutation, and hypermethylation. p16 expression has been found up regulated in prostate cancer ([@b36-grsb-2007-313]). CpG island methylation of p16 gene, which has been observed in prostate cell lines, appears rare in prostate cancer tissues ([@b57-grsb-2007-313]; [@b64-grsb-2007-313]; [@b50-grsb-2007-313]; [@b120-grsb-2007-313]; [@b83-grsb-2007-313]; [@b105-grsb-2007-313]). Furthermore, in prostate cancer tissues, p16 methylation has been frequently detected at exon2 compared to the promoter region; however, the significance of this event is unclear ([@b120-grsb-2007-313]; [@b83-grsb-2007-313]). In addition, cyclin D2 promoter methylation has been detected, and correlated with disease progression in prostate cancer ([@b128-grsb-2007-313]). Regarding the CIP/KIP family, although epigenetic silencing of p57 is not a rare event, the other members p21 and p27 are rarely methylated in prostate tumors ([@b83-grsb-2007-313]; [@b10-grsb-2007-313]; [@b79-grsb-2007-313]; [@b101-grsb-2007-313]).

The 14-3-3 families of proteins play an important role in regulating cellular signaling involved in cancer development ([@b59-grsb-2007-313]). Among the different genes in this family, the 14-3-3sigma (SFN) isoform has been mostly implicated in human cancer. It is thought to act as a tumor suppressor gene by inhibiting cell cycle progression ([@b58-grsb-2007-313]; [@b59-grsb-2007-313]). CpG island methylation and loss of SFN expression have been detected in different types of cancer ([@b59-grsb-2007-313]; [@b102-grsb-2007-313]). SFN, a negative cell cycle regulator, has been found down regulated in prostate cancer cell lines and tissues by promoter hypermethylation ([@b102-grsb-2007-313]; [@b108-grsb-2007-313]; [@b100-grsb-2007-313]). SFN methylation has been also observed in BPH tissues ([@b56-grsb-2007-313]).

Hypomethylation and Prostate Cancer
===================================

A second type of aberrant methylation, hypomethylation, has also been described to occur in neoplastic cells. This form of DNA methylation occurs principally in many tumors of advanced stages and is thought to be genome-wide ([@b146-grsb-2007-313]). Hypomethylation or demethylation of normally methylated DNA may lead to structural and functional alterations of the genome. Two types have been described: (i) global or genomic hypomethylation, which is defined as the decrease in overall level of DNA cytosine methylation, and affects different types of repetitive sequences, and (ii) localized or gene-specific hypomethylation, which refers to a decrease in methylation compared to the normal level. Both types have been involved in human cancers ([@b30-grsb-2007-313]).

In general, global and gene hypomethylation in prostate cancer has not been well studied thus far. Global hypomethylation has been observed in a few prostate cancer cases. Prostate cancer cells showed a decrease in overall methylation compared to normal prostate cells ([@b12-grsb-2007-313]). Moreover, other studies found associations between global hypomethylation and clinical and metastatic stage of prostate cancer ([@b148-grsb-2007-313]; [@b80-grsb-2007-313]).

Gene-specific hypomethylation refers to the loss of methylation of gene promoters that are normally methylated. Several studies have found gene hypomethylation in prostate cancers. The following genes affected by this mechanism are urokinase plasminogen activator, cancer/testis antigen gene (CAGE), heparanase, cytochrome P450 1B1 (CYP1B1) and X (inactivate)-specific transcript (XIST) ([Table 2](#t2-grsb-2007-313){ref-type="table"}). All of these genes have been shown over-expressed and associated with specific stage of the disease ([@b54-grsb-2007-313]; [@b129-grsb-2007-313]; [@b17-grsb-2007-313], [@b18-grsb-2007-313]; [@b123-grsb-2007-313]; [@b161-grsb-2007-313]; [@b88-grsb-2007-313]). These preliminary studies suggest of gene hypomethylation as a potential mechanism in the up-regulation of genes involved in prostate cancer. This needs to be explored further.

Histone Modifications and Prostate Cancer
=========================================

The basic structural unit of DNA, chromatin, is composed of nucleosomes. Nucleosome consists of an octamer of core histones, H2A, H2B, H3 and H4, tightly bound to DNA, and the strength of this interaction is crucial to regulate gene expression ([@b84-grsb-2007-313]; [@b85-grsb-2007-313]; [@b156-grsb-2007-313]; [@b49-grsb-2007-313]). Five posttranslational modifications of histone proteins, involved in regulation of gene expression, have been identified: acetylation, phosphorylation, methylation, ubiquitination, and ADP-ribosylation; ([@b143-grsb-2007-313]; [@b66-grsb-2007-313]). DNA and histones are linked functionally to control transcription and repair. It has been shown that methylated DNA recruits histone deacetylase (HDAC) through methyl-DNA binding proteins (MBPs); consequently, DNA methylation/histone deacetylation cross talk has been suggested to influence gene silencing ([@b73-grsb-2007-313]; [@b114-grsb-2007-313]; [@b9-grsb-2007-313]; [@b43-grsb-2007-313]; [@b72-grsb-2007-313]; [@b35-grsb-2007-313]; [@b121-grsb-2007-313]).

In prostate cancer, a number of in vitro studies provide evidence that promoter hypermethylation and histone deacetylation interact to maintain chromatin in its inactive state. These studies have shown that combined treatment with the histone deacetylase inhibitor, Trichostatin A, and demethylating agents 5-aza-cytidine or 5-aza-2′-deoxycytidine led to reversing epigenetic silencing of several genes. A loss of hypermethylation in the promoter and concomitant gene activation has been observed for a number of tumor suppressor genes in various prostate cancer cell lines. For example, DAB2IP in PC-3 cell line, RARβ gene in LNCaP, PC-3, and DU145 cell lines, GSTP1 in LNCaP cells, and MAGE a gene that encodes tumor-associated antigens in LNCaP and DU145 cells ([@b16-grsb-2007-313]; [@b113-grsb-2007-313]; [@b155-grsb-2007-313]; [@b173-grsb-2007-313]). These studies provide more evidence for a causative role of DNA hypermethylation and histone modification in the silencing of gene expression.

Conclusion
==========

In this review, we have described a limited number of genes frequently dysregulated in prostate cancer, postulated to be due to changes in methylation status. Studies show that prostate tumors have a large number of genes with epigenetic changes, indicating that epigenetics plays an important role in the development and progression of prostate cancer. Given this, studies that further knowledge in the epigenetic events related to prostate carcinogenesis may lead to the development of molecular markers for screening and risk assessment, as well as therapeutic targets for preventing and controlling this disease.
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###### 

Summary of genes frequently hypermethylated in prostate cancer.

  Genes/pathways                                      Function                                    Methylation frequency
  --------------------------------------------------- ------------------------------------------- -----------------------
  **DNA damage repair**                                                                           
  Glutathione S Transferase Pi (GSTP1)                Intracellular detoxification                70% to 100%
  O-6-Methylguanine DNA-Methyltransferase (MGMT)      Remove alkyl adducts from O^6^-guanine      0% to 75%
  **Cell adhesion**                                                                               
  Endothelin Receptor B (ENDRB)                       Tumor suppressor                            38% to 83%
  E-cadherin (CDH1)                                   Tumor suppressor: invasion and metastasis   13% to 70%
  **CD44**                                            Tumor suppressor: metastasis                33% to 68%
  Adenomatous Polyposis Coli (APC)                    Tumor suppressor                            27% to \>85%
  **Hormonal responses**                                                                          
  Retinoic Acid Receptor beta (RARβ)                  Tumor suppressor                            30% to 90%
  Androgen Receptor (AR)                              Hormone regulation                          0% to 28%
  Estrogen Receptor Alpha (ERα)                       Hormone regulation                          19% to 95%
  Estrogen Receptor Beta (ERβ)                        Hormone regulation                          \<20% to 100%
  **Signal transduction**                                                                         
  Ras association domain family 1A (RASSF1A)          Tumor suppressor: cell growth               53% to 100%
  Death-Associated Protein Kinase1 (DAPK1)            Regulator of cell death                     1% to 36%
  **Cell growth, invasion, metastasis**                                                           
  Tissue Inhibitors of Metalloproteinase-2 (TIMP-2)   Tumor suppressor                            78.5%
  Tissue Inhibitors of Metalloproteinase-3 (TIMP-3)   Tumor suppressor                            6% to 96.6%
  **Cell cycle**                                                                                  
  CDKN2A/p16                                          Tumor suppressor                            3% to 66%
  CDKN1C/p57                                          Tumor suppressor                            56%
  CDKN1A/p21                                          Tumor suppressor                            6%
  CDKN1B/p27                                          Tumor suppressor                            6%
  Cyclin D2                                           Cell cycle regulator                        32%
  14-3-3sigma (SFN)                                   Cell cycle regulator                        40% to 100%

**References:** (GSTP1): [@b77-grsb-2007-313]; [@b176-grsb-2007-313]; [@b178-grsb-2007-313]; [@b180-grsb-2007-313]. (MGMT): [@b77-grsb-2007-313]; [@b83-grsb-2007-313]; [@b105-grsb-2007-313]; [@b178-grsb-2007-313]; [@b180-grsb-2007-313]. (ENDRB): [@b69-grsb-2007-313]; [@b119-grsb-2007-313]; [@b176-grsb-2007-313]; [@b180-grsb-2007-313]. (CDH1): [@b93-grsb-2007-313]; [@b105-grsb-2007-313]; [@b177-grsb-2007-313]. (CD44): [@b82-grsb-2007-313]; [@b176-grsb-2007-313], [@b177-grsb-2007-313]. (APC): [@b77-grsb-2007-313]; [@b105-grsb-2007-313]; [@b180-grsb-2007-313]. (RARβ): [@b105-grsb-2007-313]; [@b113-grsb-2007-313]; [@b178-grsb-2007-313]; [@b176-grsb-2007-313]. (AR): [@b81-grsb-2007-313]; [@b112-grsb-2007-313]; [@b147-grsb-2007-313]; [@b178-grsb-2007-313]. (ERα): [@b93-grsb-2007-313]; [@b147-grsb-2007-313]; [@b180-grsb-2007-313]. (ERβ): [@b122-grsb-2007-313]; [@b147-grsb-2007-313]; [@b183-grsb-2007-313]. (RASSF1A): [@b77-grsb-2007-313]; [@b86-grsb-2007-313]; [@b98-grsb-2007-313]; [@b105-grsb-2007-313]; [@b176-grsb-2007-313] and [@b177-grsb-2007-313]; [@b180-grsb-2007-313]. (DAPK1): [@b77-grsb-2007-313]; [@b105-grsb-2007-313]; [@b178-grsb-2007-313]. (TIMP-2): [@b134-grsb-2007-313]. (TIMP-3): [@b70-grsb-2007-313]; [@b178-grsb-2007-313]. (CDKN2A/p16): [@b64-grsb-2007-313]; [@b83-grsb-2007-313]; [@b105-grsb-2007-313]. (CDKN1C/p57): [@b101-grsb-2007-313]. (CDKN1A/p21): [@b83-grsb-2007-313]. (CDKN1B/p27): [@b83-grsb-2007-313]. (Cyclin D2): [@b128-grsb-2007-313]. (SFN): [@b56-grsb-2007-313]; [@b100-grsb-2007-313]; [@b108-grsb-2007-313].

###### 

Summary of hypomethylated genes in prostate cancer.

  Genes                                       Function                                                   Methylation frequency   References
  ------------------------------------------- ---------------------------------------------------------- ----------------------- -----------------------
  Urokinase Plasminogen Activator (uPA)       Tumor invasion and metastasis                              75% to 96.9%            [@b129-grsb-2007-313]
  Cancer/testis Antigen Gene (CAGE)           Cell cycle control: cellular proliferation                 34%                     [@b18-grsb-2007-313]
  Heparanase                                  Tumor invasion and metastasis                              8.5 to 30.5%            [@b123-grsb-2007-313]
  Cytochrome P4501B1 (CYP1B1)                 Hydroxylation of estrogens and activation of carcinogens   5.7 to 17.1%            [@b161-grsb-2007-313]
  X (inactivate)-specific transcript (XIST)   X-chromosome inactivation                                  \<4% to \>12%           [@b88-grsb-2007-313]
